FBC
VRTX icon

Fairfield, Bush & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Fairfield, Bush & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291K Sell
586
-25
-4% -$11.1K 0.14% 104
2026
Q1 		$273K Sell
611
-15
-2% -$6.99K 0.15% 108
2025
Q4 		$284K Sell
626
-45
-7% -$19.4K 0.15% 96
2025
Q3 		$263K Sell
671
-20
-3% -$8.36K 0.13% 102
2025
Q2 		$308K Hold
691
– – 0.17% 88
2025
Q1 		$335K Sell
691
-88
-11% -$41K 0.21% 84
2024
Q4 		$314K Sell
779
-622
-44% -$288K 0.18% 86
2024
Q3 		$652K Sell
1,401
-445
-24% -$214K 0.39% 64
2024
Q2 		$865K Sell
1,846
-220
-11% -$95.5K 0.52% 51
2024
Q1 		$864K Buy
2,066
+670
+48% +$283K 0.51% 51
2023
Q4 		$568K Buy
+1,396
New +$516K 0.33% 65
2023
Q3 		– Sell
-16
Closed -$5.63K – 507
2023
Q2 		$5.63K Buy
+16
New +$5.39K ﹤0.01% 366
2022
Q3 		– Sell
-16
Closed -$5K – 459
2022
Q2 		$5K Buy
+16
New +$4.28K ﹤0.01% 356

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fairfield, Bush & Co's VRTX Position: Q2 2026 in Review

Fairfield, Bush & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 4.1% in Q2 2026, selling an estimated $11.1K and leaving 586 shares worth $291K. The position accounts for 0.14% of the portfolio, ranked #104.

Fairfield, Bush & Co first reported a position in VRTX in Q2 2022 and has held it in 13 quarters since. The position peaked at $865K in Q2 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Fairfield, Bush & Co held 586 shares of Vertex Pharmaceuticals worth $291K as of Q2 2026.
  • Fairfield, Bush & Co sold 25 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.1K.
  • Vertex Pharmaceuticals made up 0.14% of Fairfield, Bush & Co's portfolio in Q2 2026, its #104 holding.
  • Fairfield, Bush & Co first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • Fairfield, Bush & Co's Vertex Pharmaceuticals position peaked at $865K in Q2 2024.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fairfield, Bush & Co's 13F filing for Q2 2026, filed 13 Aug 2026.